Cerebrolysin vs NNZ-2591
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: FPE 1070
Cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by EVER Neuro Pharma in Austria. It is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not FDA-approved in the United States. Despite decades of use abroad, the human evidence remains genuinely contested.
Also: Cyclo-L-glycyl-L-2-allylproline, Cyclic glycine-proline analog
NNZ-2591 is Neuren Pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cGP), a small ring-shaped molecule the body makes when it breaks down IGF-1. It is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: Phelan-McDermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and Angelman and Pitt Hopkins syndromes behind it. Phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Cerebrolysin | NNZ-2591 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The proposed idea is that Cerebrolysin's small peptides act like the body's own neurotrophic factors, the molecules such as BDNF and NGF that help neurons survive, grow, and form connections. Researchers hypothesize it engages neurotrophic signaling pathways and may protect neurons from injury and support repair after stroke or brain trauma. It is important to be clear that the exact active components and mechanism are not fully defined, partly because it is a complex biological mixture rather than one purified molecule. So the neurotrophic-mimic story is a plausible hypothesis supported by some lab data, not a precisely mapped pathway. | Cyclic glycine-proline is thought to fine-tune IGF-1 activity in the brain by changing how IGF-1 binds to its carrier protein IGFBP-3. A 2014 Scientific Reports study proposed that cGP nudges IGF-1 activity up when it is low and down when it is high, a normalizing effect rather than a simple boost. NNZ-2591 adds an allyl group to the proline ring, making it resistant to enzymes and able to reach the brain after oral dosing. Trial protocols also describe reduced neuroinflammation and support for synapse function in animal models. It is a close cousin of trofinetide in spirit (both are small IGF-1-derived molecules from the same company), but the exact way it helps in these genetic syndromes has not been pinned down in humans. |
| Common Dosing | 20-32 mg/day (a 60mg vial reconstituted in 3 mL bacteriostatic water gives 20 mg/mL) Once or twice daily, with amounts above 20 mg divided between morning and evening, escalated gradually | 12 mg/kg twice daily (phase 2 target trial dose) Twice daily |
| Administration | Subcutaneous (research) or intravenous/intramuscular (clinical literature) | Oral liquid |
| Typical Duration | 8-16 week protocols for research-scale subQ; 10-20 day cycles for clinical IV | 13 weeks in phase 2 and phase 3 trials, with 12-month open-label extensions |
| Best Time to Take | Morning | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Cerebrolysin has been tested in many human trials, but the quality and consistency of that evidence is the real story. A Cochrane systematic review on vascular dementia (Cui and colleagues, 2019) concluded that intravenous Cerebrolysin may improve cognition and global function, but cautioned the findings were not definitive because of high risk of bias and heterogeneity across studies. Cochrane reviews of acute ischemic stroke have similarly found insufficient or inconclusive evidence and have flagged a possible signal of increased non-fatal serious adverse events in some analyses. The Alzheimer's Drug Discovery Foundation's Cognitive Vitality review rates the human evidence as mixed and far from conclusive. So while it is a real, widely prescribed drug in many countries, the claim that it reliably improves brain outcomes is not established to Western regulatory standards, and many of the supporting trials come from a narrow set of investigators and sponsors. | The human data so far come from three small, open-label phase 2 trials of 13 weeks each, all with twice-daily oral dosing titrated up to a target of 12 mg/kg. In Phelan-McDermid syndrome (18 children, published in Neurology Genetics in 2026), 10 of 14 efficacy measures improved significantly from baseline, including clinician and caregiver global ratings, behavior, sleep and communication, and the drug was well tolerated with mostly mild to moderate side effects. Angelman syndrome (reported August 2024) showed a mean CGI-I of 3.0, with 11 of 13 children rated improved by clinicians. Pitt Hopkins syndrome (reported May 2024) showed improvement in 6 of 11 children on clinician-rated severity. The big caveat: none of these had a placebo group, and rare-disease trials with caregiver-rated outcomes are especially prone to placebo effects. A planned Prader-Willi trial was withdrawn before enrolling anyone. The real test is Koala, a randomized, double-blind, placebo-controlled phase 3 trial in about 160 children aged 3 to 12 with Phelan-McDermid syndrome (first patient dosed February 2026; estimated primary completion late 2027), with an open-label extension started in 2026. The FDA has given the program Fast Track, Rare Pediatric Disease and Orphan Drug designations. Neuren has also started work in neonatal hypoxic-ischemic encephalopathy, which is still preclinical. |
Frequently Asked Questions: Cerebrolysin vs NNZ-2591
What is the difference between Cerebrolysin and NNZ-2591?
Cerebrolysin is a cognitive peptide that cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by ever neuro pharma in austria. it is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not fda-approved in the united states. despite decades of use abroad, the human evidence remains genuinely contested. NNZ-2591 is a cognitive peptide that nnz-2591 is neuren pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cgp), a small ring-shaped molecule the body makes when it breaks down igf-1. it is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: phelan-mcdermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and angelman and pitt hopkins syndromes behind it. phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Cerebrolysin or NNZ-2591?
Neither is universally "better" - the choice depends on your specific goals. Cerebrolysin is typically used for cognitive purposes, while NNZ-2591 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Cerebrolysin and NNZ-2591 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Cerebrolysin and NNZ-2591 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.